PMID- 11673409
OWN - NLM
STAT- MEDLINE
DCOM- 20020117
LR  - 20220310
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 20
DP  - 2001 Oct 1
TI  - Pharmacogenetics.
PG  - 2261-7
AB  - Pharmacogenetics is the variability of drug response due to inherited 
      characteristics in individuals. Drug metabolizing enzymes have been studied for 
      decades, first as chemical reactions and, more recently, as specific 
      polymorphisms of known molecules. With the availability of whole-genome 
      single-nucleotide polymorphism (SNP) maps, it will soon be possible to create an 
      SNP profile for patients who experience adverse events (AEs) or who respond 
      clinically to the medicine (efficacy). Proof-of-principle experiments have 
      demonstrated that high density SNP maps in chromosomal regions of genetic linkage 
      facilitate the identification of susceptibility disease genes. Whole-genome SNP 
      mapping analyses aimed at determining linkage disequilibrium (LD) profiles along 
      an ordered human genome backbone are in progress. SNP 'fingerprints' or SNP 
      PRINTs(sm) will be used to identify patients at greater risk of an AE, or those 
      patients with a greater chance of responding to a medicine. As LD maps for 
      various ethnic populations are constructed, the number of SNPs necessary to 
      measure for an individual will decrease. Standardized pharmacogenetic maps for 
      drug registration and post-marketing surveillance will result in safer, more 
      effective and more cost-efficient medicines. The timing of these pharmacogenetic 
      applications will occur over the next 5 years. In contrast, the benefits of 
      pharmacogenomic applications such as the identification of new tractable targets 
      will not be visible as new medicines for 7-12 years, due to the lengthy drug 
      development and registration processes.
FAU - Roses, A D
AU  - Roses AD
AD  - GlaxoSmithKline, Five Moore Drive - 5616, Research Triangle Park, NC 27709, USA. 
      adr69412@gsk.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Humans
MH  - *Pharmacogenetics
RF  - 29
EDAT- 2001/10/24 10:00
MHDA- 2002/01/18 10:01
CRDT- 2001/10/24 10:00
PHST- 2001/10/24 10:00 [pubmed]
PHST- 2002/01/18 10:01 [medline]
PHST- 2001/10/24 10:00 [entrez]
AID - 10.1093/hmg/10.20.2261 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Oct 1;10(20):2261-7. doi: 10.1093/hmg/10.20.2261.